ISAR-TRIPLE: Six Weeks vs. Six Months Clopidogrel in DES Patients Receiving Triple Therapy

Shortening clopidogrel therapy from six months to six weeks after drug eluting stent (DES) implantation in patients receiving concomitantly aspirin and oral anticoagulation is not superior in terms of net clinical outcomes, based on findings from the ISAR TRIPLE Trial presented at TCT 2014.

Additional Resources
  • TCT 2014 Meeting Coverage
  • ISAR TRIPLE Trial Summary
  • AnticoagEvaluator Mobile App & Other Resources 
  • ISAR TRIPLE is the largest randomized trial to date investigating triple therapy after stenting and the first trial evaluating duration of triple therapy. Study investigators randomized 614 patients with DES implantation to either six weeks clopidogrel or six months clopidogrel.

    Overall, study investigators said shortening the clopidogrel timeframe did not reduce the incidence of major bleeding in DES patients. I addition, it did not increase the incidence of the composite of ischemic events.

    Moving forward, study investigators said these findings will help in defining the optimal duration of triple therapy after DES implantation.

    Keywords: Platelet Aggregation Inhibitors, Drug-Eluting Stents, Ticlopidine, Purinergic P2Y Receptor Antagonists

    < Back to Listings